Affordable Access

Influenza vaccination in the elderly: improved antibody response with Imuthiol (Na diethyldithiocarbamate) adjuvant therapy.

Authors
  • Lesourd, B M
  • Vincent-Falquet, J C
  • Deslandes, D
  • Musset, M
  • Moulias, R
Type
Published Article
Journal
International Journal of Immunopharmacology
Publisher
Elsevier
Publication Date
Jan 01, 1988
Volume
10
Issue
2
Pages
135–143
Identifiers
PMID: 2836324
Source
Medline
License
Unknown

Abstract

To improve influenza vaccine efficacy in hospitalized elderly, we compared the evolution of antibody level after vaccination in three patient groups. A sample of apparently primo vaccinated elderly were randomized to receive either Imuthiol (Na diethyldithiocarbamate: group 1) or a placebo (group P). They were compared to patients who had been vaccinated annually for several years (group C). All patients were immunized in the same week. Antibody responses increase within 15 days to reach a plateau in group P and C, while they continue to increase in the Imuthiol treated group, reaching higher antibody levels 30 days after vaccination. This higher antibody rise in group I is essentially due to higher antibody responses in patients with initially low antibody levels and who exhibited at least a four-fold antibody rise. This effect of Imuthiol on influenza antibody responses was observed in spite of a lower nutritional status in this group, a condition that induces lower antibody responses. The higher antibody responses observed in the Imuthiol treated group allow longer protection against influenza.

Report this publication

Statistics

Seen <100 times